|
| 36219809 | Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. | J Clin Oncol | 2023 |
| 37943491 | Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629. | Dermatol Ther (Heidelb) | 2023 |
| 37925894 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. | Oral Oncol | 2023 |
| 36535566 | Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. | Ann Oncol | 2023 |
| 35333599 | Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. | J Clin Oncol | 2022 |
| 35690517 | Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]. | Ann Oncol | 2022 |
| 36264378 | First-line pembrolizumab⿿±⿿chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048. | Int J Clin Oncol | 2022 |
| 35240857 | Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma. | Future Oncol | 2022 |
| 32407532 | Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. | J Natl Cancer Inst | 2021 |
| 34558040 | Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. | Dermatol Ther (Heidelb) | 2021 |
| 34293460 | Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. | Ann Oncol | 2021 |
| 33239737 | Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. | Mod Pathol | 2021 |
| 32673170 | Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). | J Clin Oncol | 2020 |
| 30509740 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. | Lancet | 2019 |
| 31609223 | p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply. | Lancet | 2019 |
| 28623430 | A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). | Breast Cancer Res Treat | 2017 |
| 25605838 | CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. | J Clin Oncol | 2015 |
| 27140800 | Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients. | Clin Pharmacol Drug Dev | 2015 |
| 26114161 | Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer. | JAMA Oncol | 2015 |
| 24590635 | Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. | J Clin Oncol | 2014 |
| 25130998 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. | Lancet Oncol | 2014 |
| 22200869 | Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. | Breast Cancer Res Treat | 2012 |
| 22776042 | Lymphatic space invasion is not an independent predictor of outcomes in early stage breast cancer treated by breast-conserving surgery and radiation. | Breast J | 2012 |
| 22580118 | Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer. | Int J Radiat Oncol Biol Phys | 2012 |
| 20732766 | Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. | Int J Radiat Oncol Biol Phys | 2011 |
| 21510857 | Circulating tumor cells in breast cancer: a tool whose time has come of age. | BMC Med | 2011 |
| 20443785 | History of smoking is associated with younger age at diagnosis of breast cancer. | Breast J | 2010 |
| 19167492 | Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. | J Steroid Biochem Mol Biol | 2009 |
| 19373863 | Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. | J Surg Oncol | 2009 |
| 18621608 | Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. | Clin Breast Cancer | 2008 |
| 20477435 | Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. | Biomark Med | 2008 |
| 19128429 | By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy. | Breast Cancer Res | 2008 |
| 17440819 | SERMs for the treatment and prevention of breast cancer. | Rev Endocr Metab Disord | 2007 |
| 17977500 | Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative. | J Natl Compr Canc Netw | 2007 |
| 17719781 | Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. | Breast | 2007 |
| 17379430 | Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. | Int J Radiat Oncol Biol Phys | 2007 |
| 17308087 | Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. | Cancer Res | 2007 |
| 16510595 | Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. | Cancer Res | 2006 |
| 17061250 | Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. | Cancer | 2006 |
| 16103749 | Importance of rational pre-clinical development: gemcitabine comes of age. | Cancer Biol Ther | 2005 |
| 16144943 | Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. | Clin Cancer Res | 2005 |
| 12069836 | Lysophosphatidic acid is a bioactive mediator in ovarian cancer. | Biochim Biophys Acta | 2002 |
| 11706404 | The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. | Semin Oncol | 2001 |
| 8530540 | Further characterization of the human cell multiprotein DNA replication complex. | J Cell Biochem | 1995 |
| 2071113 | Determination of lineage and clonality in diffuse lymphomas using the polymerase chain reaction technique. | Hum Pathol | 1991 |